Skip To Main Content

Vabysmo (faricimab-svoa)

Publications icon

Publications

Visit PubMed.gov to browse a listing of published scientific literature about Vabysmo®.

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomized, double-masked, phase 3, non-inferiority trials
Heier JS et al. Lancet 2022 Feb;399(10326):729-740.

VIEW

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
Wykoff CC, Abreu F, Adamis AP, et al. Lancet 2022 Feb 19;399:741-755.

VIEW

Scientific congresses icon

Scientific Congresses

Genentech maintains a presence at in-person and virtual scientific congresses worldwide. Find Genentech-sponsored posters and presentations from recent congresses at Medically.gene.com.

November 2-5, 2022
Onsite

September 30 - October 3, 2022
Onsite

September 1-4, 2022
Onsite/virtual

July 13-16, 2022
Onsite

June 8-11, 2022
Onsite

May 15-18, 2022
Onsite/virtual

May 1-4, 2022
Onsite/virtual

February 11-12, 2022
Virtual

November 12-15, 2021
Onsite/virtual

November 3-6, 2021
Onsite

October 17-20, 2021
Virtual

October 8-12, 2021
Onsite

September 29 - October 2, 2021
Virtual

September 9-12, 2021
Virtual

May 1-7, 2021
Virtual

February 12-13, 2021
Virtual

February 6-7, 2021
Virtual

Clinical trials icon

Clinical Trials

Find information about active clinical research for Vabysmo® at ClinicalTrials.gov and information about our research at Genentech Clinical Trials.

Additional resources icon

Additional Resources

For additional information or assistance regarding Vabysmo®, use the links below.

Connect with a Medical Science Liaison

Browse the Genentech Medical Information Library